Gliclazide and Oesophagitis haemorrhagic - a phase IV clinical study of FDA data


Oesophagitis haemorrhagic is found among people who take Gliclazide, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Gliclazide and have Oesophagitis haemorrhagic. It is created by eHealthMe based on reports of 22,504 people who have side effects when taking Gliclazide from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 05, 2023

22,504 people reported to have side effects when taking Gliclazide.
Among them, 9 people (0.04%) have Oesophagitis haemorrhagic.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in type 2 diabetes. eHealthMe is studying from 22,714 Gliclazide users for its effectiveness, alternative drugs and more.

What is Oesophagitis haemorrhagic?

Oesophagitis haemorrhagic (bleeding with inflammation of oesophagus) is found to be associated with 262 drugs and 132 conditions by eHealthMe.

Number of Gliclazide and Oesophagitis haemorrhagic reports submitted per year:

Could Gliclazide cause Oesophagitis haemorrhagic?

Gender of people who have Oesophagitis haemorrhagic when taking Gliclazide *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Oesophagitis haemorrhagic when taking Gliclazide *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Gliclazide *:

  1. Metformin: 9 people, 100.00%
  2. Hydroxocobalamin: 9 people, 100.00%
  3. Senna: 8 people, 88.89%
  4. Paracetamol: 7 people, 77.78%
  5. Alendronic Acid: 5 people, 55.56%
  6. Binosto: 1 person, 11.11%

Common side effects people have besides Oesophagitis haemorrhagic *:

  1. Oral Pain: 9 people, 100.00%
  2. Unresponsive To Stimuli: 5 people, 55.56%
  3. Nausea And Vomiting: 5 people, 55.56%
  4. Malaise (a feeling of general discomfort or uneasiness): 5 people, 55.56%
  5. Hallucinations (sensations that appear real but are created by your mind): 5 people, 55.56%
  6. Confusional State: 5 people, 55.56%

Common conditions people have *:

  1. Hip Fracture: 8 people, 88.89%
  2. Osteoporosis (bones weak and more likely to break): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and have Oesophagitis haemorrhagic?

Check whether Oesophagitis haemorrhagic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Oesophagitis haemorrhagic and when was it recovered:

Expand to all the drugs that have ingredients of gliclazide:

Alternative drugs to, pros and cons of Gliclazide:

Common Gliclazide side effects:

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Oesophagitis haemorrhagic treatments and more:

COVID vaccines that are related to Oesophagitis haemorrhagic:

All the drugs that are associated with Oesophagitis haemorrhagic:

All the conditions that are associated with Oesophagitis haemorrhagic:

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide (the active ingredients of Gliclazide) and Gliclazide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: